Methemoglobinemia Following Intravenous Iron Treatment Administered As Ferric Carboxymaltose or Ferric Derisomaltose in Patients with Anemia
Status: Recruiting
Location: See location...
Intervention Type: Other, Diagnostic test
Study Type: Observational
SUMMARY
Methemoglobinemia as a side effect of treatment with intravenous iron has not previously been described. This study aims to assess methemoglobin levels in patients with anemia following treatment with intravenous iron, administered as ferric carboxymaltose or ferric derisomaltose.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
⁃ for patients in the cohort study:
• anemia
• prescription of administration of intravenous iron (ferric carboxymaltose or ferric derisomaltose)
⁃ for patients in the case report:
• patients with severe anemia who developed methemoglobinemia following administration of ferric derisomaltose
Locations
Other Locations
Sweden
Center of Clinical Research Dalarna
RECRUITING
Falun
Time Frame
Start Date: 2024-09-02
Estimated Completion Date: 2025-12
Participants
Target number of participants: 80
Treatments
Ferric derisomaltose
Adult patients with anemia scheduled for administration of ferric derisomaltose as prescribed in routine care.
Ferric carboxymaltose
Adult patients with anemia scheduled for administration of ferric carboxymaltose as prescribed in routine care.
Case reports
Patients with severe anemia who developed methemoglobinemia after intravenous administration of ferric derisomaltose.
Related Therapeutic Areas
Sponsors
Leads: Claudia Seiler